Botulinum Toxin Formulation with Cationic Carrier

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current botulinum toxin formulations are painful upon injection, cause unwanted paralysis due to diffusion, and induce antigenic responses, leading to reduced efficacy and safety concerns due to long half-life and immune system reactions.

Innovation Solution

Development of injectable compositions with botulinum toxin non-covalently associated with positively charged carrier molecules, such as cationic peptides, to enhance penetration, stability, and reduce antigenicity, thereby improving safety and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If botulinum toxin is administered in conventional formulations, then therapeutic effect is achieved, but antigenic response is induced leading to reduced efficacy

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidantigenic response

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses albumin as an intermediary carrier molecule to deliver botulinum toxin. The albumin-toxin complex allows the toxin to be administered while reducing direct immune recognition, thereby maintaining therapeutic efficacy while minimizing antigenic response and antibody formation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates a composite formulation consisting of botulinum toxin non-covalently associated with albumin. This composite structure combines the therapeutic properties of the toxin with the immunomodulatory and protective properties of albumin, reducing antigenicity while maintaining efficacy.

Inventive Principle:

Principle #40Composite materials

2Reliability

If botulinum toxin formulations are administered, then muscle paralysis effect is achieved, but diffusion causes unwanted paralysis in surrounding areas

Engineering Contradiction:

Improvemuscle paralysis effectVSAvoidunwanted diffusion

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Albumin serves as a mediator that controls the distribution and diffusion of botulinum toxin. The albumin-toxin complex limits uncontrolled diffusion while maintaining the desired muscle paralysis effect at the injection site, preventing unwanted paralysis in surrounding areas.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Duration of action of stationary object

If botulinum toxin is administered repeatedly, then therapeutic benefit is maintained, but immune system reactions increase reducing safety

Engineering Contradiction:

Improvetherapeutic benefit durationVSAvoidimmune system reactions

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

Albumin acts as a protective intermediary that reduces immune system recognition of botulinum toxin during repeated administrations. This allows maintenance of therapeutic benefit over time while minimizing safety concerns related to immune reactions and antibody formation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The albumin carrier provides beforehand protection against immune system reactions. By pre-complexing the toxin with albumin, the formulation cushioning effect reduces the impact of repeated administrations on the immune system, maintaining safety during long-term therapy.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

4Reliability

If conventional botulinum toxin formulations are used, then treatment is effective, but injection is painful

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidinjection pain

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The albumin-toxin composite formulation modifies the physical and chemical properties of the injection solution, reducing irritation and pain upon injection while maintaining treatment effectiveness. The complexation with albumin softens the harsh effects of pure toxin administration.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of positively charged carriers in botulinum toxin formulations results in reduced antigenicity, enhanced potency, longer duration of clinical efficacy, faster onset, and improved stability, minimizing diffusion and immune response issues.

Implementation Method 1

botulinum toxin non-covalently associated with a positively charged carrier molecule

Methodology Applied

Scientific EffectNon-covalent association: Adsorption

Implementation Method 2

positively charged carrier molecules, such as cationic peptides, to enhance penetration

Methodology Applied

Scientific EffectElectrostatic interaction: Ion Repulsion/Attraction

Data Source

PatentUS20240058628A1Injectable botulinum toxin formulations

Publication Date: 2024.02.22 REVANCE THERAPEUTICS INC

AI summary

This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.